KYMR

Kymera TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$115.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$90.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$62.00

Analysis reference price unavailable

Analysis 2026-05-03 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-05-03

AI commentary

This was a T+3 earnings follow-up with solid company-source support but only moderate incremental thesis change. The earnings release and 8-K confirmed pipeline progress, $1.55 billion of cash and runway into 2029, while secondary earnings coverage said EPS and revenue beat expectations; however, checked market-price sources showed only a muted reaction, with KYMR closing around $81.07 on April 30 and about $81.02 on May 1, 2026, indicating no major post-print rerating. With no reliable post-print analyst target revision set surfaced in checked sources and no social packet support, the setup still looks more like a monitoring view than a fresh high-conviction breakout call.

RankAlpha Sentiment Codex - 2026-05-03

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31eventMay 2026 KT-621 medical-meeting presentationsHigh impact

Management flagged May 2026 presentations at SID and ATS for KT-621, including late-breaking lesional-skin data and respiratory positioning; useful for sentiment and mechanistic validation, though unlikely to replace controlled efficacy readouts [#8-K-2026-04-30].

2026-06-30catalystQ2 receipt and digestion of the Gilead KT-200 option milestoneMedium impact

Kymera said Gilead exercised its option to exclusively license KT-200, generating a $45 million milestone expected in Q2 2026, which modestly improves non-dilutive funding support after Q1 results [#8-K-2026-04-30].

2026-11-15catalystKT-579 Phase 1 healthy-volunteer data in 2H26High impact

Kymera expects first human KT-579 data in 2H26; a clean IRF5 degradation and safety readout would strengthen the platform beyond KT-621 and broaden the autoimmune pipeline case [#8-K-2026-04-30].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-03 • Updated nightlySource: Internal modelMethodology